who

We

are
We are a vibrant science and technology company

Watch our movie
To us, it’s about discovering and developing for life in all its vibrancy, drawing our unique expertise in health care, life science and performance materials.

Our ideas are everywhere from cancer therapies and laboratory tools to the display of your smartphone or the effect pigment coating of your car.

CuRious mInds dedicated to human progress

Our global network of scientists, experts and thought leaders is driven by the passion to explore and the prospect of making a meaningful difference in the world.
We are known as Merck internationally except for the United States and Canada, where we operate as EMD Serono in the biopharmaceutical business, MilliporeSigma in the life science business, and EMD Performance Materials in the high-tech materials business.

Merck KGaA
Darmstadt, Germany

Every day, our nearly 52,000 employees work in 66 countries to make a positive difference to millions of people’s lives by creating more joyful and sustainable ways to live.
We take responsibility for our products, the environment and the people around us – especially our employees and the communities in which we operate. In doing so, safety and ethical aspects matter just as much to us as business success.
MeRck’s Global Responsibility

Corporate Responsibility
We identify and initiate opportunities to create shared value across Merck.
We collaborate in addressing major global challenges by delivering solutions that enable
• economic
• social
• environmental
value within and beyond business operations.

Global Health
We improve health of underserved populations in low- and middle-income countries
• through Merck's innovations in science & technology
• in close collaboration with our external partners

Our overarching principle is shared value: we identify societal and environmental needs that we can service with our assets in a win-win approach for society and Merck.
We improve the health of underserved populations in low- and middle-income countries through Merck’s science & technology innovation, and in close collaboration with our external partners.
**PURPOSE**  
*Why we do it*

We improve the health of underserved populations in low- and middle-income countries through Merck’s science & technology innovation, and in close collaboration with our external partners.

---

**OPERATING PRINCIPLES**  
*How we do it*

- We develop innovative solutions that address unmet GH needs
- We engage cross-sector partners to amplify impact
- We create business opportunities to serve unmet needs sustainably

---

**PRIORITY AREAS**  
*What we do*

1. Schistosomiasis elimination
2. Malaria and infectious diseases product innovation
3. Creation of new shared value opportunities, including access, health system strengthening and capacity building along the value chain

---

**TARGET GROUPS**  
*We want change*

- For underserved populations
- For our business units
- For our employees
- For external partners and stakeholders

---

1 Defined as elimination of schistosomiasis as a public health problem  

HSS, health systems strengthening
**Innovative solutions** that address unmet GH needs:
We develop new integrated drug, diagnostic, and vector control solutions for the infectious disease space, and we take a leading role in the elimination of schistosomiasis.

**Cross-sector partners** to amplify impact:
We participate in multi-stakeholder GH platforms and the ATM Index to help shape the agenda and progress of the SDGs and catalyze access alliances for our solutions.

**Business opportunities** to serve unmet needs sustainably:
We help Merck’s business to improve the health of the underserved in a sustainable way by providing access to Merck’s portfolio across the 3 Merck business sectors.

**Our principle:**
Shared value
Using **Shared value** to improve the health of underserved populations.

**Our guiding principle is shared value**

We identify societal and environmental needs that we can service with our assets in a win-win approach for society and Merck.
GH Committed to the UN SDGs
Leaving No One Behind

17 Universal goals + 169 Targets + 230 Indicators ➔ 2030

Objectives
- Building on the success of the Millennium Development Goals
- Ensuring sustainable social and economic progress worldwide
- Integrating and balancing economic, social and environmental dimensions
- Ambitious agenda for all 7 billion of the world’s people, not just the poorest
- New models of partnership

“Sustainable business can unlock at least US$12 trillion in new market value and repair the economic system.”

Better Business, Better World,
The report of the Business & Sustainable Development Commission, January 2017
GH main contribution into UN SDGs

“Sustainable business can unlock at least US$12 trillion in new market value and repair the economic system.”


Leaving no one behind
Universal Health Coverage (UHC)

“Universal health coverage is both a SDG goal in itself and a means for implementing other goals.”

implementation of public health interventions, disease prevention and health promotion

Global UHC movement due to: 1) importance of access to health; 2) importance of health in the economy; 3) growing burden of NCDs.

SDG 3.8

“Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.”
The Global Health Leaders, Goals, Drivers

A healthier future for all: individuals, communities, countries

Merck Global Health Institute
Jutta Reinhard-Rupp

Develop innovative products in the fight against malaria and infectious diseases

Global Health
Manfred Klevesath

One Merck collaboration

Access to Health
Frédérique Santerre

Eliminate schistosomiasis as a public health burden

Merck Schisto Elimination Program
Johannes Waltz

Create new shared value opportunities, health system strengthening...

Global Schisto Alliance

Merck as a trusted, responsible and equal partner in GH for our stakeholders

Create new shared value opportunities, health system strengthening...

and capacity-building throughout the value chain

Global Health Manfred Klevesath

Shared value and new opportunities across business units, better One Merck collaboration

A healthier future for all: individuals, communities, countries

One Merck collaboration

Our team members as motivated, inspired and responsible citizens and leaders of change

One Merck collaboration

One Merck collaboration
Develop transformative health solutions to support control and elimination programs related to infectious disease carrying a major toll on children.

Develop a cross-sectoral collaboration among all stakeholders to meet the challenging target of the global elimination of schistosomiasis.

Improving sustainable access to high-quality health solutions for unserved and underserved populations, regardless of their geographic location or ability to pay.
Our priority areas

Eliminate schistosomiasis as a public health burden

Malaria and infectious diseases product innovation

Creation of new shared value opportunities, including access, health system strengthening and capacity building along the value chain
Eliminate schistosomiasis as a public health burden
Schistosomiasis, the second most devastating tropical disease in terms of public health burden and economic impact.

More than 200 million people worldwide suffer from schistosomiasis.

> 90% of those affected live in sub-Saharan Africa.

Key Facts on Schistosomiasis
The cycle of transmission

- Schistosomiasis is caused by **flatworms** and is spread through **stagnant water**.
- The **infection rate** is especially high among **children**.
- **Chronic symptoms** that result are learning disabilities, anemia, malnutrition.
- It leads to **chronic diseases**, e.g. genital schistosomiasis, bladder cancer.
Our goal is the elimination of schistosomiasis as a public health burden through an integrated approach.
2007
Begin of the donation program in partnership with WHO

250 M
Committed annual donation

1 B
PZQ tablets donated

400 M
Treatments of school-aged children enabled

46
African countries supplied
Transmission

• Innovative tools to control the vector
• Water & sanitation control methods

Treatment

• Next generation of compounds (drug discovery)
• New Ped PZQ formulation for preschoolers
• PZQ optimized formulation
• PZQ use for Female Genital Schistosomiasis

Diagnostics

• Sensitive and specific diagnostics
• New biomarkers to develop complementary diagnostics

Health System Strengthening

• Initiative for higher education for local researchers
• Capacity building: from infrastructures to operational research
Within the scope of a public-private partnership (PPP), we are developing a formulation of praziquantel for preschoolers.

**VISION:**

Reduce the global disease burden of schistosomiasis.

**MISSION:**

Develop, register and provide access to a suitable pediatric praziquantel formulation to treat schistosomiasis in preschoolers, including infants and toddlers.

[www.pediatricpraziquantelconsortium.org/](http://www.pediatricpraziquantelconsortium.org/)
Through a health education project in Ethiopia with the NALA Foundation, which develops impactful tools to promote changes in hygiene behavior.

Through a number of research programs with local academia and institutions which aim at fostering expertise and know-how in developing countries.
Life changing behaviors

Good hygiene behavior is crucial to prevent the infection with schistosomiasis.

We are looking into opportunities to include water, sanitation and hygiene i.e. WASH activities and tools into our approach.
#MakingSchistory

**Merck Global Health** at the heart of a large community of partners.

2007: **World Health Organization (WHO)** – our strong partner in the fight against schistosomiasis.

2012: **Pediatric Praziquantel Consortium** – today formed by 8 partners and 2 main funders.

2014: **Global Schistosomiasis Alliance (GSA)** as a key convening platform for the global schistosomiasis community.

The goal: move towards **global elimination** of this insidious disease.